Evidence map›Paper›PMID 40476514›Full record

ArticleFuture oncology (London, England)2025

Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.

Lucia Masarova, Srdan Verstovsek, Francesca Palandri, Ruben Mesa, Claire Harrison, Gautam Sajeev, Boris Gorsh, Ryan Simpson, Sang Cho, Zhaohui Wang and 3 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lucia MasarovaThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Srdan VerstovsekThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Francesca PalandriIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Ruben MesaAtrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
Claire HarrisonGuy's and St Thomas' NHS Foundation Trust, London, UK.
Gautam SajeevAnalysis Group, Boston, MA, USA.
Boris GorshGSK plc, Philadelphia, PA, USA.
Ryan SimpsonAnalysis Group, Boston, MA, USA.
Sang ChoAnalysis Group, Boston, MA, USA.
Zhaohui WangGSK plc, Philadelphia, PA, USA.
Catherine EllisGSK plc, Philadelphia, PA, USA.
Seán ConlonGSK plc, Reading, UK.
James SignorovitchAnalysis Group, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo perform an indirect treatment comparison of safety outcomes between the Janus kinase (JAK) inhibitors momelotinib and fedratinib in patients with myelofibrosis.

methodsAdverse events (AEs) for JAK inhibitor - naive and - experienced populations occurring in ≥ 10% of patients treated with momelotinib (SIMPLIFY-1/SIMPLIFY-2/MOMENTUM) or fedratinib (JAKARTA/JAKARTA-2) in phase 2/3 trials were evaluated using matching-adjusted indirect comparisons.

resultsRisk of any-grade or grade 3/4 anemia, diarrhea, nausea, and treatment-emergent AEs leading to dose reductions was lower with momelotinib in both populations; any-grade thrombocytopenia was also significantly less likely in JAK inhibitor - naive patients.

conclusionsMomelotinib showed a favorable safety profile vs fedratinib, including significantly lower risks of key hematologic and gastrointestinal AEs - such as anemia, diarrhea, and nausea - over 24 weeks.

Indexed as

BenzamidesJanus Kinase InhibitorsPrimary MyelofibrosisPyrimidinesPyrrolidinesSulfonamidesAgedBenzenesulfonamidesFemaleHumansMaleMiddle AgedTreatment OutcomeBenzamidesBenzenesulfonamidesfedratinibJanus Kinase InhibitorsN-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamidePyrimidinesPyrrolidinesSulfonamidesfedratinibindirect treatment comparisonJAK inhibitormomelotinibMyelofibrosissafety

Identifiers

PMID40476514
PMCPMC12218749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.